MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why HROW Stock surged +2.04% Today — RQD Quant Desk Flash
$29.99 +2.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $30.17
Harrow Inc. (HROW) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (75% profit margin, 43% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $1.12B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $30.17 (+0.61%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 15.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE+5.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HROW)Realized 20D OHLCV Swing Band: ±10.2%
Deterministic 5-Pillar Attribution (71/100 Composite)
🔍 WHY HROW SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 15.8% FCF Margin ($43.0M FCF) & 75.1% Gross Margin
▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (21% of score)
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 38.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk12/20 pts (-8 pt drag)
Balance-sheet & 10-K footnote risk deducts 8 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$29.36-7.1% Next Q
63
Q2 (-2Q)Grade B-$27.28+4.3% Next Q
66
Q3 (-1Q)Grade B-$28.44+5.5% Next Q
68
CurrentGrade B-$29.99+6.8% Hist 90D α
71
Trajectory: C+ (63) → B- (71)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the HROW Bull Thesis Could Fail
Even with a 71/100 (B-) score, HROW faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 72.6% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($32.86) or 200D SMA ($38.35) invalidates the momentum regime and cuts Target Base ($31.74) toward Bear Floor ($24.59).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HROW• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HROW Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HROW Stock surged +2.04% Today — RQD Quant Desk Flash
Harrow Inc. (HROW) surged +2.04% to $29.99, trading at 11% of its 52-week range ($26.96 – $54.85). High-quality cash engine (75% profit margin, 43% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 11% of its 52-week range ($26.96 – $54.85) with RSI-14 at 38.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.2% around $29.99 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 75.1% gross margin and $43.0M annual free cash flow.
Live HROW Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (HROW Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HROW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.01%▼ DESCENDING CHANNEL
2026-10-30O $29.69H $30.05L $28.08C $29.99VOL 335.2K
RES: $34.75SUP: $26.78SMA50: $32.86SMA200: $38.35
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HROW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
31.7%/yr Implied 5Y Growth
vs. +36.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HROW today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HROW. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HROW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HROW)
Health Care Rank #86 of 1016
⚔️ MNKD vs HROW Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HROW vs. MNKD, SPTX, CTY, AVLN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Harrow Inc. (HROW) ranks #86 by composite RQD confidence (71/100, grade B-) and #349 by equity capitalization ($1.12B). Within this direct 5-issuer industry benchmark cohort, HROW leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HROW
ACTIVE
Harrow Inc. | B- | 71/100 | — | 75.1% | 42.9% | +2.04% | $1.12B | Benchmark Subject |
| MNKD MannKind Corporation | C | 63/100 | — | 92.3% | 54.5% | +2.04% | $1.13B | /mnkd-vs-hrow → |
| SPTX Seaport Therapeutics Inc. | D+ | 56/100 | — | — | — | +3.53% | $1.13B | /sptx-vs-hrow → |
| CTY City Therapeutics Inc. | C- | 61/100 | — | — | — | +2.26% | $1.11B | /cty-vs-hrow → |
| AVLN Avalyn Pharma Inc. | D | 49/100 | — | — | — | -0.12% | $1.14B | /avln-vs-hrow → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001360214In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harrow Inc. (HROW) reported GAAP revenue of $272.3M (+36.4% vs. FY2024 revenue of $199.6M , and +109.2% cumulative change since FY2023) , GAAP net income of -$5.1M, operating cash flow of $43.9M, and free cash flow of $43.0M (+280.6% YoY). On the balance sheet, HROW closed FY2025 with $399.5M in total assets against $0 in total debt (Altman Z-Score: 2.67, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $272.3M | -$5.1M | $43.9M | $43.0M | $399.5M | — |
| FY2024 (FY) | 2024-12-31 | $199.6M | -$17.5M | -$22.2M | -$23.8M | $389.0M | — |
| FY2023 (FY) | 2023-12-31 | $130.2M | -$24.4M | $3.8M | $3.8M | — | — |
3. HROW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HROW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Harrow Inc. (NASDAQ: HROW) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $29.99 (+2.04% 1D, market cap $1.12B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HROW ranks #86 in composite RQD confidence.
How does HROW compare to MNKD and SPTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HROW carries a Roarable B- (71/100 RQD), trailing P/E of N/A, gross margin of 75.1%, and ROIC of 42.9%. By comparison, MNKD (MannKind Corporation) holds a C grade (63/100 RQD, P/E N/A, ROIC 54.5%, cap $1.13B) and SPTX (Seaport Therapeutics Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $1.13B). Among the 5-stock peer group, HROW leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HROW?
Per HROW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001360214), Harrow Inc. generated $272.3M in revenue (+36.4% YoY), -$5.1M in net income, and $43.0M in free cash flow against $399.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (75% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HROW trading relative to its 50-day, 200-day, and 52-week technical levels?
HROW last traded at $29.99 (+2.04% on volume of 321,095 shares), positioning the stock -8.73% below its 50-day simple moving average ($32.86) and -21.80% below its 200-day simple moving average ($38.35). Across its 52-week range of $26.96 to $54.85, HROW sits at the 10.9% percentile with a 14-day RSI of 38.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($26.93 to $33.05).
HROW Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HROW stock moving today?
Why HROW Stock surged +2.04% Today — RQD Quant Desk Flash. High-quality cash engine (75% profit margin, 43% return on capital) with steady institutional support.